The use of intravitreal anti-VEGF treatment for retinopathy of prematurity has been steadily increasing [46] since it is much easier to administer than laser photocoagulation, results in a rapid reduction of angiogenic drive and retinal neovascularization, and allows for further maturation of the peripheral retinal vasculature. Here, VEGFA is linked to retinopathy of prematurity.